Bristol-Myers Squibb (BMY) Receives European Commission Approval for Onureg as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia

Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia

Onureg is the first and only once-daily, frontline oral maintenance therapy in the European Union (EU) for patients with a broad range of acute myeloid leukemia (AML) subtypes

In the pivotal QUAZAR® AML-001 study, Onureg significantly improved overall survival and relapse-free survival in patients with AML

PRINCETON, N.J.--(BUSINESS... More